Abstract P6-13-02: Subcutaneous trastuzumab for the treatment of HER2+ breast cancer in Canada: A cost-minimization study

Abstract

Abstract Background: There is an urgent need to alleviate the pressure on healthcare resources and decrease treatment burden for patients. Recently, a new fixed dose subcutaneous (SC) formulation of trastuzumab was approved by Health Canada for use in HER2-positive breast cancer (HER2+ BC) patients. Studied in multiple trials and treatment settings, the totality of evidence demonstrated similar safety and efficacy to the IV formulation as well as a strong preference for trastuzumab SC by patients and health care professionals. Objective: To estimate the incremental costs/savings associated with the use of trastuzumab SC for the treatment of HER2+ BC if reimbursed with the same provincial funding criteria as trastuzumab IV in Ontario, Canada. Methods: An Excel-based cost-minimization and budget impact model was developed to determine the economic impact of trastuzumab SC in comparison to trastuzumab IV in Ontario. Direct medical costs in the analysis included drug acquisition, drug preparation, drug administration, central venous access device (CVAD), and systemic therapy suite costs. Results: Early and metastatic HER2+ BC patients treated with trastuzumab SC are expected to generate a net cost savings to the health system compared to treatment with trastuzumab IV. Savings are estimated at $11,943 per eBC patient and $11,943 per mBC patient, representing total savings of $15.8M in Year 1, $19.4M in Year 2, and $23.0M in Year 3. The use of trastuzumab SC in these populations enhances the ability of the payer to manage drug and medical resources, while offering a therapy that is aligned with patient and clinician preferences. Citation Format: Megan Coombes, Lori Yin, Ingrid Liu, Norman Shek, Flavia Rusu, Som Mukherjee. Subcutaneous trastuzumab for the treatment of HER2+ breast cancer in Canada: A cost-minimization study [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P6-13-02.